61886 Federal Register / Vol. 72, No. 211 / Thursday, November 1, 2007 / Notices 

roster of committee members may be 

obtained from Debbie M. Jackson, 

Senior Program Analyst, National 

Center for Health Statistics, Centers for 

Disease Control and Prevention, 3311 

Toledo Road, Room 2339, Hyattsville, 

MD 20782, (301) 458–4614, 

djackson@cdc.gov; or Marjorie S. 

Greenberg, Executive Secretary, NCVHS, 

National Center for Health Statistics, 

Centers for Disease Control and 

Prevention, 3311 Toledo Road, Room 

2402, Hyattsville, Maryland 20782, 

telephone (301) 458–4245. Information 

also is available on the NCVHS home 

page of the HHS Web site http:// 

www.ncvhs.hhs.gov/. 

Should you require reasonable 

accommodation, please contact the CDC 

Office of Equal Employment 

Opportunity on (301) 458–4EEO (4336) 

as soon as possible. 

Dated: October 22, 2007. 

James Scanlon, 

Deputy Assistant Secretary for Science and 

Data Policy, Office of the Assistant Secretary 

for Planning and Evaluation. 

[FR Doc. 07–5434 Filed 10–31–07; 8:45 am] 

BILLING CODE 4151–04–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Notice of Availability of Draft Guidance 

on Allocating and Targeting Pandemic 

Influenza Vaccine 

AGENCY: Office of the Secretary, Health 

and Human Services. 

ACTION: Notice of availability. 

SUMMARY: The Department of Health and 

Human Services (HHS) and the 

Department of Homeland Security 

(DHS) are seeking public comment on 

the draft Guidance on Allocating and 

Targeting Pandemic Influenza Vaccine. 

The draft Guidance is now available on 

the HHS Web site. 

DATES: Submit comments on or before 

December 31, 2007. 

Instructions for Submitting 

Comments: Electronic responses are 

preferred and may be addressed to 

Panfluvaccine@hhs.gov. Written 

responses should be addressed to U.S. 

Department of Health and Human 

Services, Room 434E, 200 Independence 

Avenue, SW., Washington, DC 20201, 

Attention: Pandemic Influenza Vaccine 

Prioritization Guidance Comments. A 

copy of the Notice and the full text of 

the draft Guidance are also available on 

the PandemicFlu.Gov Web site at 

http://www.pandemicflu.gov/vaccine/ 

prioritization.html and at http:// 

www.aspe.hhs.gov/panflu/ 

vaccinepriorities.html. Please follow 

instructions for submitting responses. 

The submission of comments in 

response to this notice should not 

exceed 25 pages, not including 

appendices and supplemental 

documents. Any information you 

submit will be made public. 

Consequently, do not send proprietary, 

commercial, financial, business 

confidential, trade secret, or personal 

information that you do not wish to be 

made public. 

Public Access: Responses to this 

notice will be available to the public in 

the HHS Public Reading Room, 200 

Independence Avenue, SW., 

Washington, DC 20201. Please call (202) 

690–7453 between 9 a.m. and 5 p.m. to 

arrange access. 

FOR FURTHER INFORMATION CONTACT: HuiHsing Wong, M.D., Office of the 

Assistant Secretary for Planning and 

Evaluation, (202) 205–0519. 

SUPPLEMENTARY INFORMATION: Influenza 

viruses have threatened the health of 

animal and human populations for 

centuries. A pandemic occurs when a 

novel strain of influenza virus emerges 

that has the ability to infect and be 

passed between humans. Because 

humans have little immunity to the new 

virus, a worldwide epidemic, or 

pandemic, can ensue. 

Three human influenza pandemics 

occurred in the 20th century. In the 

U.S., each pandemic led to illness in 

approximately 30 percent of the 

population and death in between 2 in 

100 and 2 in 1000 of those infected. It 

is projected that a modern pandemic, 

absent effective control measures, could 

result in the death of 200,000 to 2 

million people in the U.S. alone. 

A critical part of the United States 

Government (USG) strategy to control 

the spread of a pandemic and reduce its 

health and societal impact is through 

the use of vaccines. The USG is working 

toward a goal of expanding domestic 

influenza surge capacity to produce 

pandemic influenza vaccines for the 

entire population within six months of 

a pandemic declaration. However, at the 

beginning of a pandemic, the limited 

supply of existing pandemic influenza 

vaccines will require that their 

distribution and administration be 

prioritized. 

Accordingly, the Homeland Security 

Council Implementation Plan for the 

National Strategy for Pandemic 

Influenza required the Department of 

Health and Human Services (HHS) in 

coordination with the Department of 

Homeland Security (DHS) to convene a 

federal interagency working group to 

draft a guidance to assist State and local 

governments, communities, tribal and 

territorial governments, and the private 

sector in planning an effective and 

consistent pandemic response. The USG 

embarked on a rigorous and 

collaborative process to seek input from 

all interested parties in developing a 

strategy to emerge from a pandemic 

with minimal levels of illness, death, 

and disruption to our society and 

economy. 

The draft Guidance on Allocating and 

Targeting Pandemic Influenza Vaccine 

outlines the USG’s goal of targeting the 

early production of pandemic vaccines 

to reduce the impact on health and 

minimize disruption to society and the 

economy and describes the scientific 

and ethical framework for how this 

guidance was developed. As part of the 

guidance, a tiered prioritization for 

vaccines in severe pandemics is being 

proposed with the following objectives 

considered to be the most important: (1) 

Protect those who are essential to the 

pandemic response and provide care for 

persons who are ill; (2) protect those 

who maintain essential community 

services; (3) protecting children; and (4) 

protect workers who are at greater risk 

of infection as a result of their job. 

Protecting those who maintain 

homeland and national security was 

also considered a significant Federal 

objective. The ultimate goal of 

pandemic vaccination is to provide 

vaccines to all persons in the United 

States who choose to be vaccinated by 

6 months after the declaration of a 

pandemic. 

With this notice, the USG requests 

comment from the public and interested 

stakeholders on the draft Guidance on 

Allocating and Targeting Pandemic 

Influenza Vaccine. 

Specifically, the USG invites 

comments on the following: 

The framework for establishing 

pandemic influenza vaccine priorities, 

including the—

(1) approach for defining: 

a. Target groups, 

b. The clusters of target groups in the 

categories, 

c. The levels within categories, 

d. The tiers across categories. 

(2) The extent to which the 

prioritization guidance addresses the 

stated program objectives. 

(3) The extent to which the guidance 

is likely to lead to fair and ethical 

allocation and targeting of pandemic 

influenza vaccine across the population. 

The text of the draft guidance is 

available in html and pdf formats 

through the PandemicFlu.Gov Web site 

at http://www.pandemicflu.gov/vaccine/ 

prioritization.html and the HHS Web 

site at http://www.aspe.hhs.gov/panflu/ 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 72, No. 211 / Thursday, November 1, 2007 / Notices 61887 

vaccinepriorities.html. For those who 

may not have Internet access, a hard 

copy can be requested from the point of 

contact, Hui-Hsing Wong, Office of the 

Assistant Secretary for Planning and 

Evaluation (202) 205-0519. 

Date: October 24, 2007. 

RADM W. Craig Vanderwagen, 

Assistant Secretary for Preparedness and 

Response. 

[FR Doc. 07–5435 Filed 10–31–07; 8:45 am] 

BILLING CODE 4151–04–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Board on Radiation and 

Worker Health (ABRWH or Advisory 

Board), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 11 a.m.–4 p.m., 

November 27, 2007. 

Place: Audio Conference Call via 

Federal Telecommunications System 

Conferencing. The USA toll free dial in 

number is 1–866–659–0537 with a pass 

code of 9933701. 

Status: Open to the public, but 

without a public comment period. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000 to advise the 

President on a variety of policy and 

technical functions required to 

implement and effectively manage the 

new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines 

which have been promulgated by the 

Department of Health and Human 

Services (HHS) as a final rule, advice on 

methods of dose reconstruction which 

have also been promulgated by HHS as 

a final rule, advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program, and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort (SEC). 

In December 2000, the President 

delegated responsibility for funding, 

staffing, and operating the Advisory 

Board to HHS, which subsequently 

delegated this authority to the CDC. 

NIOSH implements this responsibility 

for CDC. The charter was issued on 

August 3, 2001, renewed at appropriate 

intervals, most recently, August 3, 2007, 

and will expire on August 3, 2009. 

Purpose: This Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary 

on whether there is a class of employees 

at any Department of Energy facility 

who were exposed to radiation but for 

whom it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters To Be Discussed: The agenda 

for the conference call includes: FY 

2008 New Site Profiles and New 

Procedures for SC&A; Procedures to 

Select New Contractor for ABRWH; 

Work Group Updates; Sandia-Livermore 

Update and Future Activities; Chapman 

Valve Reports from DOE and DOL; Dow 

Chemical Report from DOE; SEC and 

Site Profile Matrices Update; 

Subcommittee for Dose Reconstruction 

Reviews Report of the 4th and 5th Sets 

of Individual Dose Reconstructions, and 

the Summary Report on the First 100 

Cases; Rocky Flats Update; Discussion 

of Board Procedures; Status of and Plans 

for Future Board Activities; and Board 

Working Time. 

The agenda is subject to change as 

priorities dictate. Because there is not a 

public comment period, written 

comments may be submitted. Any 

written comments received will be 

included in the official record of the 

meeting and should be submitted to the 

contact person below well in advance of 

the meeting. 

Contact Person for More Information: 

Dr. Lewis V. Wade, Executive Secretary, 

NIOSH, CDC, 4676 Columbia Parkway, 

Cincinnati, Ohio 45226. Telephone 

(513) 533–6825, Fax (513) 533–6826. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: October 25, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–21505 Filed 10–31–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Committee on 

Interdisciplinary, Community-Based 

Linkages; Notice of Request for 

Nominations 

SUMMARY: The Health Resources and 

Services Administration (HRSA) is 

requesting nominations to fill seven (7) 

upcoming vacancies on the Advisory 

Committee on Interdisciplinary, 

Community-Based Linkages (ACICBL). 

Authority: 42 U.S.C. 294f, Section 756 

of the PHS Act, as amended. The 

Advisory Committee is governed by 

provisions of Public Law (Pub. L.) 92–

463, as amended (5 U.S.C. Appendix 2) 

which sets forth standards for the 

formation and use of advisory 

committees. 

DATES: The Agency must receive 

nominations on or before December 31, 

2007. 

ADDRESSES: All nominations are to be 

submitted by mail to Louis D. 

Coccodrilli, Designated Federal Official, 

ACICBL, Bureau of Health Professions 

(BHPr), HRSA, Parklawn Building, 

Room 9–05, 5600 Fishers Lane; 

Rockville, MD 20857. 

FOR FURTHER INFORMATION CONTACT: 

Adriana Guerra, Public Health Fellow, 

Division of Medicine and Dentistry, by 

e-mail aguerra@hrsa.gov or telephone, 

(301) 443–6194. 

SUPPLEMENTARY INFORMATION: Under the 

authorities that established the ACICBL, 

the Federal Advisory Committee Act of 

October 6, 1972 (Pub. L. 92–463), and 

section 2119 of the Act, 42 U.S.C. 00aa–

19, as added by Public Law 99–660 and 

amended, HRSA is requesting 

nominations for seven (7) voting 

members. 

The ACICBL provides advice and 

recommendations to the Secretary and 

to the Congress concerning policy, 

program development and other matters 

of significance related to 

interdisciplinary, community-based 

training grant programs authorized 

under sections 751–756, Title VII, Part 

D of the Public Health Service Act. The 

ACICBL prepares an annual report 

describing the activities conducted 

mstockstill on PROD1PC66 with NOTICES